PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Roche to launch SARS-CoV-2 rapid antigen test

Roche is gearing up to launch an antigen test able to “reliably and quickly” triage people suspected of SARS-CoV-2, with results available in just 15 minutes.

The Swiss drug giant said it would launch the SARS-CoV-2 Rapid Antigen Test later this month in partnership with SD Biosensor in all countries accepting the CE mark, which includes the UK.

The SARS-CoV-2 Rapid Antigen Test is designed for use in point of care settings for both symptomatic and asymptomatic people, helping healthcare professionals to quickly identify infection with the virus.

It also serves as an initial screening test for individuals who have been exposed to SARS-CoV-2 infected patients or a high risk environment, the firm noted.

The test has a sensitivity of 96.52% and a specificity of 99.68%, based on 426 samples from two independent study centres.

At launch, there will be 40 million SARS-CoV-2 Rapid Tests available per month, but this capacity will increase more than two-fold at the end of this year.

“As the COVID-19 pandemic persists, healthcare systems remain challenged. Testing continues to be an important focus for many countries,” said Thomas Schinecker, chief executive of Roche Diagnostics.

“Especially in the upcoming flu season, it is important to know whether a person has SARS-CoV-2 or the flu to ensure the right course of treatment. COVID-19 testing solutions that provide healthcare professionals and patients with a quick answer regarding their infection status are critical to contain the community-spread of the COVID-19 virus.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026